P. Herbolsheimer
AstraZeneca
29 Papers
67 Citations
P. Herbolsheimer is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 22 publications. Previous affiliations of P. Herbolsheimer include Washington Cancer Institute & MedStar Washington Hospital Center.
Chat about Author
Papers
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Susan M. Domchek,Sophie Postel-Vinay,Sophie Postel-Vinay,Sophie Postel-Vinay,Seock-Ah Im,Yeon Hee Park,Jean Pierre Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,Sara Bastian,Matthew G Krebs,Matthew G Krebs,Ding Wang,Saiama N. Waqar,M. Lanasa,Joon Rhee,Haiyan Gao,Vidalba Rocher-Ros,Emma V. Jones,Sakshi Gulati,Anna M. L. Coenen-Stass,Iwanka Kozarewa,Zhongwu Lai,Helen K. Angell,L Opincar,P. Herbolsheimer,Bella Kaufman,Bella Kaufman +28 more
TL;DR: Combination of olaparib and durvalumab showed promising antitumour activity and safety similar to that previously observed in olapARib and DurvalumAB monotherapy studies.
357
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
Filipa Lynce,Ana Barac,X. Geng,Chau T. Dang,Anthony F. Yu,Anthony F. Yu,Karen L. Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,Robert D. Warren,Monvadi B. Srichai,Mark Hofmeyer,A. Cunningham,P. Timothee,Federico M. Asch,Ayesha N. Shajahan-Haq,Ming Tony Tan,Claudine Isaacs,Sandra M. Swain +20 more
TL;DR: This study provides safety data of HER2-targeted therapies in patients with breast cancer and reduced LVEF while receiving cardioprotective medications and close cardiac monitoring and demonstrates the importance of collaboration between cardiology and oncology providers to allow for delivery of optimal oncologic care.
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Yvette Drew,Bella Kaufman,Susana Banerjee,A. Lortholary,Sook-Hee Hong,Young-Ae Park,Stefan Zimmermann,Patricia Roxburgh,M. Ferguson,Ricardo H. Alvarez,Susan M. Domchek,C. Gresty,Helen K. Angell,V Rocher Ros,K. Meyer,M. Lanasa,P. Herbolsheimer,M.J.A. de Jonge +17 more
TL;DR: The combination of olaparib and durvalumab was well tolerated and showed promising median PFS and DoR, and this cohort has been expanded to further explore the durability of this chemotherapy-sparing combination.
84
Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
Susan M. Domchek,Sophie Postel-Vinay,Y.-J. Bang,Young-Ae Park,Jérôme Alexandre,J.-P. Delord,Antoine Italiano,Benoit You,S Bastian,Matthew G Krebs,Ding Wang,S. Waqar,Helen K. Angell,M. Learoyd,S. Chang,C. Gresty,P. Herbolsheimer,Bella Kaufman +17 more
TL;DR: The combination of olaparib and durvalumab was well tolerated, with no apparent overlapping toxicities and the efficacy of the combination at an early time point reached the target DCR in gBRCAm HER2-negative MBC, and warrants further investigation.
52
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Susan M. Domchek,Sophie Postel-Vinay,S.-A. Im,Young-Ae Park,J.-P. Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,S Bastian,Matthew G Krebs,Ding Wang,S. Waqar,M. Lanasa,Helen K. Angell,Zhongwu Lai,C. Gresty,L Opincar,P. Herbolsheimer,Bella Kaufman +18 more
TL;DR: The data suggest that pts with fewer prior lines of chemotherapy (0/1) had higher ORR, longer mDoR, mPFS and mOS than those with 2 prior lines.
51